(MENAFN- GlobeNewsWire - Nasdaq) New York, May 25, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Generic Drugs Industry" -
Small-Molecule Generics, one of the segments analyzed in the report, is projected to record 4.8% CAGR and reach US$538.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Biosimilars segment is readjusted to a revised 19.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $122.8 Billion, While China is Forecast to Grow at 8.2% CAGR
The Generic Drugs market in the U.S. is estimated at US$122.8 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$126.8 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 5.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.
Select Competitors (Total 255 Featured)
- Astellas Pharma, Inc.
- Biocon Ltd.
- 3SBio, Inc.
- Arbor Pharmaceuticals LLC
- AristoPharma Ltd.
- Breckenridge Pharmaceutical, Inc.
- Amphastar Pharmaceuticals, Inc.
- Advance Pharmaceutical Inc.
- Celltrion, Inc.
- Acadia Pharmaceuticals, Inc.
- Acino International AG
- Acella pharmaceuticals
- Argentum Pharmaceuticals
- AustarPharma, LLC
- API Pharma Tech
Read the full report:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Impact of Covid-19 and Global Economic Update
From Pandemic to War & Inflation: ?Gloomy Outlook for 2023
Despite Signs of Easing Inflationary Conditions
Here?s How Inflationary Pressures Affect the Economy
Russia-Ukraine War, the Primary Culprit Responsible for the
Hardships
Although Past Peak in 2023, Efforts to Solve the Inflation
Puzzle Should Continue
Here?s What?s Causing Inflationary Pressures in the Global Market
Shaken by the War, Global Oil Prices Spiral and Feed
Inflationary Pressures, Guiding the World Towards a Cost of
Living Crisis: Global Average Annual Brent Crude Oil Price
(In US$ Per Barrel) for Years 2017 through 2024
War-Induced Commodity Price Increases & Broad Based Price
Pressures Mark the Return of Global Inflation to the Highest
Level Seen Since 1996: Global Inflation Rates (In %) for the
Years 2019 Through 2024
Although Facing a Lower Recession Risk, Global Economic Growth
in 2023 to Slowdown Amid War, Inflation, Elevated Interest
Rates & Marginal Easing of Inflation: World Economic Growth
Projections (Real GDP, Annual % Change) for the Years 2020
Through 2024
Recession Triggered by Uncontrolled Inflation or Unemployment,
Which is the Greater Evil? Inflation Battling Policy Measures
to Slowdown Post Pandemic Recovery in Unemployment Rates:
Global Number of Unemployed People (In Million) for Years
2019 Through 2024
How the Healthcare Industry Has Been Impacted by the Pandemic &
What?s the New Normal?
With the COVID-19 Pandemic Exposing Global Healthcare
Unpreparedness, There is Increasing Policy Led Focus on
Rebooting Health Systems Worldwide: Current & Required
Healthcare Spending as % of GDP
COVID-19 Impact on Global Pharmaceutical Supply Chain and
Generic Drugs Market
Demand for Generic Pain Killers Rises
A Prelude to Generic Drugs
Generic Drugs Market Set for a Rapid Growth
North America and Europe Dominate, Asia-Pacific to Exhibit the
Fastest Growth
India- A Significant Market
Small-molecule Generic Drugs Account for a Lion's Share,
Biosimilars Exhibit Fastest Growth
Exciting Times for Biosimilars
Competition
Generic Drugs - Global Key Competitors Percentage Market Share
in 2023 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2023 (E)
Market Opportunities
Strategies to Sustain Success
The Future of Generics & Biosimilars Look Bright amid
Persistent Barriers
Market Challenges
Factors Affecting Prices & Accessibility
Recent Market Activity
BRANDS
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Generic Drugs Enjoy Adrenaline Rush with Regulatory &
Scientific Support
R&D & Innovation Push
Efforts to Eliminate Barriers to Generics Development
Regulatory & Scientific Collaboration as Key
FDA?s Generic Drug User Free Program
Policy Support to Generic Drugs: Clearing Road to Affordable
Access to Quality Medicines
Savings in Billions
Taking GDUFA to Next Level
Pushing Competition through ANDAs
Major Push to COVID-19 Drugs
Patent Expiries Set to Widen the Addressable Market for Generic
Drugs
Patent Expiries of Select Drugs in 2020
Patent Expiries of Select Drugs in 2021
Patent Expiries of Select Drugs in 2022
Patent Expiries of Select Drugs in 2023
Patent Expiry of Select Major Drugs in the US: 2020-2023
Robust Demand for Pharmaceutical Drugs Drives Demand for
Generic Drugs
Cost Containment Measures Put Focus on Generics
Small Molecule Generics Represent the Dominant Segment
Specialty Generic Drugs Gain Popularity
Specialty Generics - The Way to Success Amid Challenges
Factors that can Provide Competitive Edge
Increasing Demand for Biosimilars, Driven by Patent Expiry of
Major Biopharmaceutical Drugs
Patent Expiries of Major Biopharmaceutical Drugs in the US and
Europe in the Recent Past
Progressive Regulatory Framework Accelerates Product Approvals &
Subsequently Market Revenues
Specific Guidelines for Biosimilars in Various Countries with
Year of Publication
Biosimilars Regulatory Agencies in Select Regional Markets
Biosimilar Approvals in the US (as of 2023)
Biosimilar Approvals in Europe (as of 2023)
Rising Healthcare Costs Drive Demand for Generic Drugs
World Healthcare Expenditure (In US$ Billion) for the Years
2017-2023
Aging Population to Propel the Demand for Generic Drugs
Global Aging Population Statistics for the 65+ Age Group in
Million by Geographic Region for the Years 2019, 2025, 2035
and 2050
Significant Increase in Number of Patients Suffering from
Chronic Diseases Fuel Demand for Generic Medicines
Global Cost of Chronic Diseases (In US$ Billion) for the Years
2018 and 2030
Fatalities by Heart Conditions - Estimated Percentage Breakdown
for Cardiovascular Disease, Ischemic Heart Disease, Stroke,
and Others
Global Cancer Incidence: Number of New Cancer Cases in Million
for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Number of New Cancer Cases and Deaths (in Million) by Region
for 2018
US Regulators Struggle to Keep Up with the Global Market
Increased Dependency on Non-US Manufacturers
Patient Trust and Traceability
Drug Supply Shortage Risks
Fixing a Broken System
Hospitals Teaming Up to Develop Own Generic Drugs to Combat
Shortages and High Prices
Use of Artificial Intelligence and Machine Learning in
Pharmaceutical Manufacturing Witnesses a Surge
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Generic Drugs Market Analysis of Annual Sales in
US$ Million for Years 2018 through 2030
Table 2: World Recent Past, Current & Future Analysis for
Generic Drugs by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 3: World Historic Review for Generic Drugs by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2021 and
% CAGR
Table 4: World 12-Year Perspective for Generic Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2018, 2023 & 2030
Table 5: World Recent Past, Current & Future Analysis for
Small-Molecule Generics by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 6: World Historic Review for Small-Molecule Generics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2021 and % CAGR
Table 7: World 12-Year Perspective for Small-Molecule Generics
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2018, 2023 & 2030
Table 8: World Recent Past, Current & Future Analysis for
Biosimilars by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 9: World Historic Review for Biosimilars by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2021 and
% CAGR
Table 10: World 12-Year Perspective for Biosimilars by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2018, 2023 & 2030
Table 11: World Recent Past, Current & Future Analysis for
Cardiovascular by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 12: World Historic Review for Cardiovascular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2021 and % CAGR
Table 13: World 12-Year Perspective for Cardiovascular by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2018, 2023 & 2030
Table 14: World Recent Past, Current & Future Analysis for
Central Nervous System (CNS) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 15: World Historic Review for Central Nervous System
(CNS) by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2021 and % CAGR
Table 16: World 12-Year Perspective for Central Nervous System
(CNS) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2018, 2023 &
2030
Table 17: World Recent Past, Current & Future Analysis for
Dermatology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 18: World Historic Review for Dermatology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2021 and
% CAGR
Table 19: World 12-Year Perspective for Dermatology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2018, 2023 & 2030
Table 20: World Recent Past, Current & Future Analysis for
Oncology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 21: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2021 and
% CAGR
Table 22: World 12-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2018, 2023 & 2030
Table 23: World Recent Past, Current & Future Analysis for
Respiratory by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 24: World Historic Review for Respiratory by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2021 and
% CAGR
Table 25: World 12-Year Perspective for Respiratory by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2018, 2023 & 2030
Table 26: World Recent Past, Current & Future Analysis for
Other Therapeutic Applications by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 27: World Historic Review for Other Therapeutic
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2018 through 2021 and % CAGR
Table 28: World 12-Year Perspective for Other Therapeutic
Applications by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2018, 2023 & 2030
A Prelude to Generic Drugs
III. MARKET ANALYSIS
UNITED STATES
Generic Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United States for 2023 (E)
Table 29: USA Recent Past, Current & Future Analysis for
Generic Drugs by Type - Small-Molecule Generics and Biosimilars -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 30: USA Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR
Table 31: USA 12-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2018, 2023 & 2030
Table 32: USA Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application - Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 33: USA Historic Review for Generic Drugs by Therapeutic
Application - Cardiovascular, Central Nervous System (CNS),
Dermatology, Oncology, Respiratory and Other Therapeutic
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2018 through 2021 and % CAGR
Table 34: USA 12-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030
CANADA
Generic Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Canada for 2023 (E)
Table 35: Canada Recent Past, Current & Future Analysis for
Generic Drugs by Type - Small-Molecule Generics and Biosimilars -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 36: Canada Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR
Table 37: Canada 12-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2018, 2023 & 2030
Table 38: Canada Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application - Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 39: Canada Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR
Table 40: Canada 12-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030
JAPAN
Generic Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Japan for 2023 (E)
Table 41: Japan Recent Past, Current & Future Analysis for
Generic Drugs by Type - Small-Molecule Generics and Biosimilars -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 42: Japan Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR
Table 43: Japan 12-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2018, 2023 & 2030
Table 44: Japan Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application - Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 45: Japan Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR
Table 46: Japan 12-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030
CHINA
Generic Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in China for 2023 (E)
Table 47: China Recent Past, Current & Future Analysis for
Generic Drugs by Type - Small-Molecule Generics and Biosimilars -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 48: China Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR
Table 49: China 12-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2018, 2023 & 2030
Table 50: China Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application - Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 51: China Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR
Table 52: China 12-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030
EUROPE
Generic Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Europe for 2023 (E)
Table 53: Europe Recent Past, Current & Future Analysis for
Generic Drugs by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR
Table 54: Europe Historic Review for Generic Drugs by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2018 through 2021 and % CAGR
Table 55: Europe 12-Year Perspective for Generic Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2018, 2023 & 2030
Table 56: Europe Recent Past, Current & Future Analysis for
Generic Drugs by Type - Small-Molecule Generics and Biosimilars -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 57: Europe Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR
Table 58: Europe 12-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2018, 2023 & 2030
Table 59: Europe Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application - Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 60: Europe Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR
Table 61: Europe 12-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030
FRANCE
Generic Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in France for 2023 (E)
Table 62: France Recent Past, Current & Future Analysis for
Generic Drugs by Type - Small-Molecule Generics and Biosimilars -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 63: France Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR
Table 64: France 12-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2018, 2023 & 2030
Table 65: France Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application - Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 66: France Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR
Table 67: France 12-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030
GERMANY
Generic Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Germany for 2023 (E)
Table 68: Germany Recent Past, Current & Future Analysis for
Generic Drugs by Type - Small-Molecule Generics and Biosimilars -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 69: Germany Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR
Table 70: Germany 12-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2018, 2023 & 2030
Table 71: Germany Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application - Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 72: Germany Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR
Table 73: Germany 12-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030
ITALY
Table 74: Italy Recent Past, Current & Future Analysis for
Generic Drugs by Type - Small-Molecule Generics and Biosimilars -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 75: Italy Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR
Table 76: Italy 12-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2018, 2023 & 2030
Table 77: Italy Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application - Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 78: Italy Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR
Table 79: Italy 12-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030
UNITED KINGDOM
Generic Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United Kingdom for 2023 (E)
Table 80: UK Recent Past, Current & Future Analysis for Generic
Drugs by Type - Small-Molecule Generics and Biosimilars -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 81: UK Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR
Table 82: UK 12-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2018, 2023 & 2030
Table 83: UK Recent Past, Current & Future Analysis for Generic
Drugs by Therapeutic Application - Cardiovascular, Central
Nervous System (CNS), Dermatology, Oncology, Respiratory and
Other Therapeutic Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 84: UK Historic Review for Generic Drugs by Therapeutic
Application - Cardiovascular, Central Nervous System (CNS),
Dermatology, Oncology, Respiratory and Other Therapeutic
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2018 through 2021 and % CAGR
Table 85: UK 12-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030
SPAIN
Table 86: Spain Recent Past, Current & Future Analysis for
Generic Drugs by Type - Small-Molecule Generics and Biosimilars -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 87: Spain Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR
Table 88: Spain 12-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2018, 2023 & 2030
Table 89: Spain Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application - Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 90: Spain Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR
Table 91: Spain 12-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030
RUSSIA
Table 92: Russia Recent Past, Current & Future Analysis for
Generic Drugs by Type - Small-Molecule Generics and Biosimilars -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 93: Russia Historic Review for Generic Drugs by Type -
Small-Molecule Generics and Biosimilars Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR
Table 94: Russia 12-Year Perspective for Generic Drugs by Type -
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2018, 2023 & 2030
Table 95: Russia Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application - Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 96: Russia Historic Review for Generic Drugs by
Therapeutic Application - Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR
Table 97: Russia 12-Year Perspective for Generic Drugs by
Therapeutic Application - Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030
REST OF EUROPE
Table 98: Rest of Europe Recent Past, Current & Future Analysis
for Generic Drugs by Type - Small-Molecule Generics and
Biosimilars - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 99: Rest of Europe Historic Review for Generic Drugs by
Type - Small-Molecule Generics and Biosimilars Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2021 and % CAGR
Table 100: Rest of Europe 12-Year Perspective for Generic Drugs
by Type - Percentage Breakdown of Value Sales for
Small-Molecule Generics and Biosimilars for the Years 2018,
2023 & 2030
Table 101: Rest of Europe Recent Past, Current & Future
Analysis for Generic Drugs by Therapeutic Application -
Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 102: Rest of Europe Historic Review for Generic Drugs by
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report:
About reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
